JAMA points out that "these adverse events, although rare, must be considered by patients who are thinking about using the drugs for weight loss because the risk-benefit calculus for this group might differ from that of those who use them for diabetes" [20]
Compared with the class of oral diabetes medications called SGLT2 inhibitors, GLP-1 therapies usually result in greater weight loss and stronger blood sugar lowering
Other potential benefits of Semaglutide GLP-1 include a decrease in blood pressure and inflammation levels
Zepbound (Tirzepatide) By targeting two hormones, GLP-1 and GIP, Zepbound enhances weight loss beyond single hormone medications
According to Bloomberg , Sandoz now expects generic semaglutide options to reach the Canadian market in the third quarter, and Canada is acting as a testing ground ahead of future patent expiries in markets such as China, India and Brazil